Voyager Acquisition Corp. (VACHW)

Voyager Acquisition Corp.’s warrants (VACHW) are the derivative securities embedded in the SPAC’s original unit offerings. When Voyager raised $253 million in August 2024, it sold 25.3 million units to public investors, each unit containing one Class A ordinary share and one-half of a redeemable warrant. The warrants began trading separately once the units split, opening the path for investors to own the upside leverage of a SPAC warrant without holding the shares.

The Origins of Voyager Warrants: SPAC Unit Economics

The SPAC warrant is a piece of financial engineering designed to align incentives between sponsors and public shareholders. When an investor buys a Voyager unit at $10, they receive the share (which can be redeemed for cash) and the partial warrant (which must be exercised or held). The warrant allows the holder to purchase one full Class A share at an exercise price set by the SPAC’s charter, typically around $11.50 to $12 per share. The half-warrant structure in Voyager’s offering meant that two warrants were needed to exercise and buy one share.

This layering served two purposes: it gave Voyager additional capital per unit (the warrant has value independent of the share), and it created leverage for investors willing to hold warrants into the post-merger entity. If Voyager completed a business combination and the merged company’s stock rose above the warrant exercise price, warrant holders would profit from the additional upside relative to share holders. If the stock fell below the exercise price, the warrants would expire worthless—a total loss for warrant holders but no further obligation.

The Structure: How VACHW Warrants Functioned

Voyager’s redeemable warrants had specific mechanics. Each whole warrant entitled the holder to purchase one Class A ordinary share at a predetermined strike price. The warrants were “redeemable,” meaning Voyager (or the merged company post-combination) could call them in if the stock price exceeded certain thresholds, forcing warrant holders to either exercise or lose the security. This redemption feature protected the company from unlimited warrant-induced dilution but created risk for warrant holders of forced exercise or expiration if they didn’t act.

Warrant holders faced three scenarios: exercise before expiration by paying the strike price and receiving shares, sell the warrant on the secondary market before it expires, or watch the warrant expire worthless if the stock never rose above the exercise price. The time value of a warrant—what investors would pay for the leverage—decayed as the expiration date approached. Warrants are therefore leveraged bets on the merged company’s performance, attractive to investors expecting strong upside and dangerous for those betting on modest or negative returns.

From IPO to Merger: What Happened to VACHW Holders

Voyager completed its merger with Veraxa Biotech in early 2025, converting from a SPAC to the public holding company Veraxa Biotech Holding AG, now trading under the ticker VRXA. The warrants transitioned into the merged entity’s capital structure—still exercisable into VRXA shares at the original strike price, still subject to the same redemption mechanics and expiration date. For VACHW holders, the value of their warrants now depended entirely on whether VRXA’s stock could climb above the warrant strike price before expiration.

The massive redemption rate—99.67% of Voyager’s Class A shares redeemed—had a significant bearing on warrant holders. Those redemptions reduced the capital available to Veraxa post-merger, raising questions about whether the operating business would be adequately funded and whether its stock could appreciate to warrant-in-the-money levels. Warrant holders were among the most exposed parties in the transaction: they had paid for leverage, but that leverage only paid off if the merged company succeeded dramatically.

The Risk and Return Profile: Why Investors Buy and Sell VACHW

Investors buy SPAC warrants for the leverage. A $1 stock price move can produce a 10% swing in warrant value if the warrant is trading near its strike price, far exceeding the 1% swing on the underlying shares. For speculators or investors with high conviction in the SPAC’s target business, that leverage is the entire appeal.

The risks, conversely, are acute. Warrants decay in value as expiration approaches, especially if the stock stays near the strike price. Unlike shares, which can be held indefinitely, warrants are a time-decaying asset with a terminal expiration date. Many SPAC warrant holders have experienced the frustration of watching warrants expire worthless after years of holding, especially as SPAC performance has disappointed the market since 2021. Redemption mechanics add another layer of uncertainty: Voyager’s redemption feature meant that if the stock rose sharply, warrant holders could be forced to exercise at an inopportune moment or see their warrants redeemed away.

For traders, VACHW’s liquidity and price swings made the warrants attractive during the period after Voyager’s IPO, when volatility was high and enthusiasm for SPAC deals was elevated. Once the merger closed and the business combination question was settled, VACHW holders faced the longer question: could Veraxa Biotech appreciate enough to make the warrants valuable? The massive shareholder redemption suggested the market had its doubts.

How to Track SPAC Warrants as an Investment

An investor monitoring VACHW would watch several key metrics: the underlying VRXA stock price versus the warrant strike price (the spread determines leverage), the time to warrant expiration (measured in months remaining), and the implied volatility of the underlying company (which affects warrant pricing). Warrant-to-share ratios became telling indicators—if VACHW traded at a steep discount relative to the share price, it signaled market pessimism about the merged company’s ability to appreciate. SEC filings disclosed the warrant exercise price and expiration terms; a quick calculation revealed how far Veraxa’s stock would need to climb for warrants to pay off.

The broader lesson of Voyager’s warrants was that SPAC leverage cuts both ways. The warrant structure aligned sponsor and shareholder incentives theoretically, but it also created a class of investors with an all-or-nothing payoff and no cushion if the merged company underperformed. As SPAC sentiment cooled and performance disappointed the market, SPAC warrants became a high-risk, high-reward bet on management’s ability to navigate a business combination and build shareholder value afterward.